Neuronetics (Neuronetics) Interest Expense : $-4.80 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Neuronetics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Neuronetics's interest expense for the three months ended in Dec. 2023 was $ -1.22 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.80 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Neuronetics's Operating Income for the three months ended in Dec. 2023 was $ -4.43 Mil. Neuronetics's Interest Expense for the three months ended in Dec. 2023 was $ -1.22 Mil. Neuronetics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Neuronetics Interest Expense Historical Data

The historical data trend for Neuronetics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Interest Expense Chart

Neuronetics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.79

-0.62

-3.30

-3.60

-4.80

Neuronetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.56	-1.25	-1.14	-1.18	-1.22

Neuronetics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.80 Mil.

Neuronetics (NAS:STIM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Neuronetics's Interest Expense for the three months ended in Dec. 2023 was $-1.22 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-4.43 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $61.63 Mil.

Neuronetics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Neuronetics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Neuronetics (Neuronetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (NAS:STIM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NRC:Germany

Address

3222 Phoenixville Pike, Malvern, PA, USA, 19355

Website

https://www.neurostar.com

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Executives

Keith J Sullivan	director, officer: President and CEO	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
William Andrew Macan	officer: Sr. VP, GC, CCO and Secretary	24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Stephen Furlong	officer: CFO	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Robert Cascella	director	C/O HOLOGIC, INC., BEDFORD MA 01730
John K Bakewell	director	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc	10 percent owner	245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper	director	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook	director	162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger	director	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Glenn P Muir	director	C/O HOLOGIC, INC., BEDFORD MA 01730
Gregory Harper	officer: VP of Prod. Dev. & Operations	C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley	director	2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie	officer: Chief Commercial Officer	C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355